AKT1 and diabetic cardiomyopathy: In summary, our newly designed dual GLP-1/GIP receptor agonist, AP5, can effectively improve the diabetic symptoms and exert protective effects on diabetic cardiomyopathy via inducing the activation of the AMPK/PI3K/AKT signaling pathway, reducing ROS production, oxidative stress and proinflammatory factors in the DCM mice.